Evolent Health (EVH) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $653 million, a 31% increase from Q1 2026.

Adjusted EBITDA: $28 million, up 27% quarter-over-quarter.

Medical Expense Ratio (MER): 95%, compared to 93% in Q1, reflecting the impact of the Highmark launch.

Cash Position: $115.7 million in unrestricted cash; net debt of $808.3 million.

Revenue by Segment:

Performance Suite: $485 million, up 50% from Q1.

Specialty Tech and Services: $78 million, down 3%.

Administrative Services: $48 million, down 3%.

2Strategic Updates and Business Highlights

Growth and Renewals: Successful renewals of three major customers and positive sales environment with new partnerships, including an oncology Performance Suite partnership expected to generate $300 million annually.

AI Initiatives: Progress in the Auth Intelligence platform, with auto-approval rates for authorizations improving significantly, enhancing operational efficiency and reducing administrative burdens.

Performance Suite Launches: Positive early indicators from the launches with Highmark and Aetna, with clinical engagement rates exceeding targets.

3Forward Guidance and Outlook

2026 Revenue Guidance: Increased to $2.6 billion - $2.7 billion.

Adjusted EBITDA Guidance: Tightened to $120 million - $135 million.

MER Expectation: Approximately 93% for the full year, with anticipated improvement in Q4.

2027 Outlook: Expected revenue growth of over 25%, driven by Performance Suite expansion despite headwinds from Medicaid membership declines and client-specific market exits.

4Bad News, Challenges, or Points of Concern

Medical Expense Ratio: Higher than expected MER due to the Highmark launch and increased acuity in exchange populations.

Membership Headwinds: Anticipated 20% decline in Medicaid expansion members, translating to a 4-5% membership drop for Evolent.

Operational Challenges: Potential margin compression due to the lower margins associated with the rapidly growing Performance Suite business.

Market Dynamics: Ongoing adjustments in client strategies and membership changes could impact revenue stability.

5Notable Q&A Insights

Reserving Practices: Management feels confident in their reserving strategies, aligning with industry standards, and sees no significant over or under-reserving.

Utilization Trends: Acuity shifts noted primarily in exchange populations, with Medicaid remaining stable.

Client-Specific Membership Declines: Some clients are exiting markets, but Evolent maintains close communication to manage expectations and adapt strategies.

Pipeline Health: The sales pipeline remains robust with opportunities for new contracts, particularly in oncology and other specialty areas, indicating strong future growth potential. Overall, Evolent Health reported strong financial performance in Q2 2026, with significant revenue growth and strategic advancements, while also navigating challenges related to membership dynamics and operational margins. The company remains optimistic about its future growth trajectory, particularly in 2027.